Plain-English translation of NCT06783829 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is a Phase I study testing SHR-4394 Injection, a new medicine designed to treat advanced prostate cancer in men whose cancer has progressed despite previous treatment. Researchers want to understand how safe this medication is, how the body processes it, and whether it helps slow or stop cancer growth. The trial will involve up to 240 men across multiple hospitals.
Many men with advanced prostate cancer eventually stop responding to standard hormone therapies, leaving them with limited treatment options. This medication is being tested to see if it offers a new way to help patients whose cancer has continued to spread or worsen.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
As a participant, you would receive injections of the study medication at a hospital or clinic, likely on a regular schedule determined by the research team. You would have multiple visits for check-ups, blood tests, and imaging scans to monitor how the medication affects your cancer and overall health. The study will track your safety and how well the treatment works over time.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
China
Phase
Safety & dosing
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Enrollment target
~240 participants
Started
January 2025
Primary completion
March 2027
Age range
18 Years โ 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Qi Shi
Jiangsu HengRui Medicine Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.